|

R-TM123 Clinical Trials

1 actively recruiting trial

Also known as: R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment

Pipeline

Phase 1: 1

Top Sponsors

  • AvenCell Europe GmbH1

Indications

  • Acute Myeloid Leukemia, in Relapse1
  • Acute Myeloid Leukemia Refractory1
  • Cancer1

Other1 trial

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.